Nasally administered appetite suppressants

• US 20070020195A1
• Filed: 06/08/2006
• Published: 01/25/2007
• Est. Priority Date: 06/08/2005
• Status: Abandoned Application

• Current Assignee: Domaine Associates LLC, Board of Supervisors of Louisiana State University Agricultural & Mechanical College (Louisiana State University System)
• Original Assignee: Board of Supervisors of Louisiana State University Agricultural & Mechanical College (Louisiana State University System)
• Inventors: Greenway, Frank, Cowley, Michael, Young, Linda
• Application Number:
  US11/449,418
• Publication Number:
  US 20070020195A1
• Time in Patent Office: Days
• US Class Current: 424/45
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/4166 having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• CPC Class Codes: A61K 31/4745 condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48
• CPC Class Codes: A61K 31/522 having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0043 Nose

Abstract

Methods are described for suppressing appetite through the intranasal administration of a sodium channel blocker. It has long been known that smell and taste are an important part of how the body prepares for a meal, for example the cephalic phase of insulin release before a meal. Depressing the sense of smell or taste in subjects prior to meals leads to decreased food intake, which ultimately leads to weight loss. The ability to deliver drugs to the CSF via intranasal application also provides anorexiant central effect.

Claims

1. A method of treating obesity in a mammal in need of such treatment comprising applying a sodium channel blocker to the mammal intranasally and administering a second compound selected from either or both of an energy expenditure drug and an anorexiant to the mammal.

2. The method of claim 1, wherein the sodium channel blocker is lidocaine.

3. The method of claim 1, wherein the sodium channel blocker is applied before meals.

4. The method of claim 1, wherein the sodium channel blocker is in the form of a gel, powder, spray, liquid, or drop.

5. The method of claim 1, further comprising administering a vasoconstrictor.

6. The method of claim 5, wherein the vasoconstrictor is selected from the group consisting of:

epinephrine, norepinephrine, endothelin, thromboxane, naphazoline nitrate, tetrahydrozoline hydrochloride, oxymetazoline hydrochloride, phenylephrine hydrochloride and tramazoline hydrochloride.

7. The method of claim 1, wherein the concentration of the sodium channel blocker is from about 0.05 to about 200 mg/ml.

8. The method of claim 1, wherein the sodium channel blocker is selected from the group consisting of:

lidocaine, mepivacaine, bupivacaine quinidine, lorcainide, procainamide, encainide, propafenone, moricizine, mexiletine, disopyramide, aprindine, phenytoin, tocainide, flecainide, procaine, benzocaine dibucaine, tetracaine, butacaine, cyclomethycaine and tetracaine.

9. The method of claim 1, further comprising the co-administration of a topical anesthetic to the oral mucosa or tongue to reduce taste sensation.

10. The method of claim 1, wherein the second compound is an energy expenditure drug.

11. The method of claim 10, wherein the energy expenditure drug is selected from caffeine, ephedrine, phentermine, zonisamide, buproprion, sibutramine, enzphetamine, and phendimetrazine.

12. The method of claim 1, wherein the second compound is an anorexiant.

13. The method of claim 12, wherein the anorexiant is selected from leptin, insulin, PYY, CNTF, Rimonabant, PPAR-delta and corticotropin-releasing factor modulators.

14. A method of treating obesity in a mammal in need of such treatment comprising applying a sodium channel blocker and a second compound selected from one or more of an energy expenditure drug, an anorexiant, a humectant, a pH buffer and a thickening agent to the mammal.

15. The method of claim 14, wherein the humectant is selected from sorbitol, mineral oil, vegetable oil, glycerol, soothing agents, membrane conditioners, sweeteners and combinations thereof.

16. The method of claim 14, wherein the pH buffer is selected from acetate, citrate, prolamine, carbonate and phosphate buffers.

17. The method of claim 14, wherein the thickening agent is selected from xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose and carbomer